Cara Therapeutics, Inc. (NASDAQ:CARA) had its price objective lowered by Cantor Fitzgerald from $26.00 to $25.00 in a report published on Friday, May 12th. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company’s stock.
CARA has been the topic of several other reports. HC Wainwright restated a buy rating and set a $30.00 price target on shares of Cara Therapeutics in a research report on Monday, April 24th. Janney Montgomery Scott set a $20.00 price target on Cara Therapeutics and gave the company a buy rating in a research report on Saturday, March 11th. Raymond James Financial, Inc. reiterated a market perform rating and set a $30.00 price objective on shares of Cara Therapeutics in a research note on Friday, April 28th. Vetr upgraded Cara Therapeutics from a strong sell rating to a sell rating and set a $17.31 price objective for the company in a research note on Thursday, March 30th. Finally, Piper Jaffray Companies reiterated an overweight rating and set a $23.00 price objective on shares of Cara Therapeutics in a research note on Friday, March 3rd. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $26.17.
Shares of Cara Therapeutics (CARA) remained flat at $17.12 during mid-day trading on Friday. 6,862,360 shares of the company traded hands. Cara Therapeutics has a 12 month low of $4.35 and a 12 month high of $20.90. The firm’s market cap is $556.52 million. The company’s 50-day moving average price is $16.60 and its 200 day moving average price is $14.71.
Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by $0.08. The company had revenue of $0.91 million during the quarter, compared to the consensus estimate of $0.11 million. During the same quarter in the previous year, the company earned ($0.39) EPS. The firm’s quarterly revenue was up 12900.0% compared to the same quarter last year. Equities analysts expect that Cara Therapeutics will post ($2.37) earnings per share for the current year.
In other Cara Therapeutics news, major shareholder Ventures Vi Lp Rho acquired 500,000 shares of the company’s stock in a transaction dated Friday, March 31st. The stock was purchased at an average price of $18.19 per share, with a total value of $9,095,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new stake in Cara Therapeutics during the first quarter worth approximately $124,000. UBS Group AG increased its stake in Cara Therapeutics by 16.9% in the first quarter. UBS Group AG now owns 10,544 shares of the biopharmaceutical company’s stock worth $194,000 after buying an additional 1,528 shares in the last quarter. Private Advisor Group LLC purchased a new stake in Cara Therapeutics during the fourth quarter worth approximately $117,000. Cambridge Investment Research Advisors Inc. increased its stake in Cara Therapeutics by 0.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 11,824 shares of the biopharmaceutical company’s stock worth $217,000 after buying an additional 60 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in Cara Therapeutics by 127.2% in the third quarter. Wells Fargo & Company MN now owns 12,007 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 6,722 shares in the last quarter. 54.84% of the stock is owned by hedge funds and other institutional investors.
About Cara Therapeutics
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
What are top analysts saying about Cara Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cara Therapeutics Inc. and related companies.